Laurel Wealth Advisors LLC Acquires 1,477 Shares of LeMaitre Vascular, Inc. $LMAT

Laurel Wealth Advisors LLC grew its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 8,205.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,495 shares of the medical instruments supplier’s stock after purchasing an additional 1,477 shares during the period. Laurel Wealth Advisors LLC’s holdings in LeMaitre Vascular were worth $124,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its position in shares of LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 287 shares during the last quarter. Geneos Wealth Management Inc. raised its position in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in LeMaitre Vascular during the 1st quarter valued at about $50,000. US Bancorp DE boosted its holdings in shares of LeMaitre Vascular by 36.0% during the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 368 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $168,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Down 0.5%

LMAT stock opened at $82.96 on Friday. The business’s 50-day moving average price is $87.22 and its 200-day moving average price is $87.07. The stock has a market cap of $1.88 billion, a P/E ratio of 40.27, a PEG ratio of 2.29 and a beta of 0.77. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $107.22.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. During the same quarter last year, the business earned $0.49 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 4th. Investors of record on Thursday, November 20th will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is 34.48%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Wells Fargo & Company decreased their target price on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Weiss Ratings restated a “hold (c+)” rating on shares of LeMaitre Vascular in a research note on Wednesday. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.